Health Canada has approved GlaxoSmithKline's Ojjaara (momelotinib) for treating myelofibrosis in adults with moderate-to-severe anaemia, based on positive results from Phase III trials.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
Health Canada approves GSK's Ojjaara for myelofibrosis in anaemia patients
